Investor Relations


Precigen Business Updates Conference Call
 Wednesday, December 26, 2018
 8:30am EST

Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON), hosted a conference call on Wednesday, December 26, at 8:30 AM ET to provide business updates, including an overview of Precigen’s recent transition from an exclusive channel collaboration model to an agile R&D engine for greater focus, full developmental control and acceleration of its core programs and an overview of the recently announced FDA clearance for the Investigational New Drug application for the first-in-class PRGN-3006 UltraCAR-T™ therapy for treatment of patients with relapsed or refractory acute myeloid leukemia and higher risk myelodysplastic syndrome. A replay of the webcast is available under the Events section of the Intrexon Investors website at